September 21, 2016
Moderna to Build State-of-the-Art Fully Integrated GMP mRNA Clinical Manufacturing Facility in Norwood, Mass.
September 13, 2016
Moderna Appoints Melissa J. Moore, Ph.D., as Chief Scientific Officer of Moderna’s mRNA Research Platform
September 07, 2016
Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine
September 07, 2016
Moderna Announces Funding Award from BARDA for $8 Million with Potential of up to $125 Million to Accelerate Development of Zika Messenger RNA (mRNA) Vaccine
July 26, 2016
Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration
July 26, 2016
AstraZeneca and Moderna Announce Filing of First Clinical Trial Application in Messenger RNA Therapeutics™ Collaboration
July 06, 2016
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis
June 29, 2016
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer
June 06, 2016
Moderna Therapeutics and Charles River Laboratories Announce Strategic Collaboration to Scale Moderna’s Nonclinical Development Efforts for Novel mRNA Therapeutics
April 04, 2016
Moderna Announces Appointment of Dr. Michael Watson as President of Valera